ORIC Pharmaceuticals, Inc.
ORIC
$9.85
$0.232.39%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 31.31M | 29.87M | 28.82M | 28.17M | 27.35M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 149.67M | 146.62M | 142.90M | 134.75M | 125.12M |
Operating Income | -149.67M | -146.62M | -142.90M | -134.75M | -125.12M |
Income Before Tax | -137.25M | -132.86M | -127.85M | -119.87M | -110.78M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -137.25 | -132.86 | -127.85 | -119.87 | -110.78 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -137.25M | -132.86M | -127.85M | -119.87M | -110.78M |
EBIT | -149.67M | -146.62M | -142.90M | -134.75M | -125.12M |
EBITDA | -148.48M | -145.48M | -141.79M | -133.69M | -124.06M |
EPS Basic | -1.89 | -1.88 | -1.83 | -1.81 | -1.76 |
Normalized Basic EPS | -1.18 | -1.18 | -1.14 | -1.13 | -1.10 |
EPS Diluted | -1.89 | -1.88 | -1.83 | -1.81 | -1.76 |
Normalized Diluted EPS | -1.18 | -1.18 | -1.14 | -1.13 | -1.10 |
Average Basic Shares Outstanding | 290.36M | 282.58M | 278.89M | 265.70M | 252.56M |
Average Diluted Shares Outstanding | 290.36M | 282.58M | 278.89M | 265.70M | 252.56M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |